ABR-217620
From Kidney Cancer Resource
Contents |
Overview
ABR-217620 is a new and experimental treatment, a product of Active Biotech Research AB of Sweden. It is made of 2 proteins. The first one recognises renal cancer cells. The second one stimulates the immune system to attack the cancer cells. It does this by activating some of the white blood cells (called T cells).
Renal cell cancer is the most common type of kidney cancer. Advanced kidney cancer may be treated with biological therapy, chemotherapy, radiotherapy or surgery, or a combination of these.
Interferon is a type of biological therapy and is often used to treat advanced kidney cancer.
Trial Specific Phase 3 UK
A trial looking at ABR-217620 in combination with interferon for advanced renal cell cancer
The aim of this trial is to see if a combination of ABR-217620 and interferon works better than interferon alone.
Disclaimer
Kidney Cancer Resource (KCR) is not influenced by sponsors. The information contained herein is not intended as a substitute for the advice of an appropriately qualified and licensed physician or other licensed health care provider. The information provided here is for educational and information purposes only. Early accurate Diagnosis (Dx.) saves lives. Please check with a physician if you suspect you are ill, never ignore Symptoms. To help your health care specialist make an accurate Diagnosis please keep notes of dates, times and details of your Symptoms. We are not offering medical advice nor do we consider links, individuals or articles accessed through this site to be offering medical advice.
E&OE - Errors & Omissions Excepted
As much of the information posted on this Web Site for peoples convenience is of a medical or technical nature, and may be a matter of life or death the E&OE is a Disclaimer showing that to the best of our ability information is accurate and correctly written or transcribed. Before acting on information on this site you are responsible for checking it with your relevant medical team. We can not be held responsible for any Errors & Omissions made; nor for information on links and articles provided in good faith.
